Sandwich, UK - 28 May 2025: Discovery Park has launched applications for its immersive business growth programme, ‘Discovery Spark’, seeking early-stage companies in cardiovascular and cardiometabolic health.
Partnered with health-specialist venture capital firm Zinc, the initiative offers expert-led business skills sessions and the opportunity to secure £250k Zinc investment.
Selvita is the first contract research organisation (CRO) to license a Chemical Protein Stability Assay developed and patented by Medicines Discovery Catapult (MDC) to help identify and prioritise drug candidates faster.
MDC’s Chemical Protein Stability Assay (CPSA) is a distinctive technology used to assess target engagement. It can be applied at every step of the drug discovery process to support drug development, screening, and optimisation.
Creative Biolabs is dedicated to helping researchers overcome gene therapy delivery research challenges with its wide technical support and services.
EI Innovate is our annual engagement event that provides insight into the Earlham Institute's research, exploring opportunities for innovation and collaboration.
At the Earlham Institute, we aim to achieve impact from our research and expertise through collaborations and partnerships.
When it comes to unforeseen research disruptions, the most successful lab operations professionals hope for “if” but plan for “when.” Yet, a survey found that only 51% of businesses have continuity plans. Business continuity plans (BCPs) ensure labs can maintain critical functions, quickly resume normal operations, and prevent the loss of valuable research in the event of interruptions. This guide explores why and how to create a business continuity plan for your laboratory.
The 5th Oligonucleotides for CNS Summit unites a select group of industry-leading biologists, chemists, C-level executives, platform tech experts, DMPK and clinical pharmacologists, all tackling the unique challenges of CNS delivered ASOs, siRNAs, miRNAs and saRNAs. Check out the 2025 agenda:
• Maxion Therapeutics expands its Cambridge headquarters and doubles the size of its offices and laboratory space
• Howard Group provides tailored real estate solution to support the biotech’s growth
Cambridge, 20th May 2025: Leading regional property investor and developer Howard Group, is delighted to announce that pioneering biotechnology company Maxion Therapeutics has more than doubled its footprint at Unity Campus.
Partnership with SCINCO strengthens international sales and technical support channels in key region as part of ongoing global expansion
Creative Biolabs is at the forefront of creating stem cell therapy, working with researchers to make new scientific advancements.
Induced pluripotent stem cells (iPSCs) contain the unprecedented possibility of differentiating into almost every cell in the body, which holds vast avenues for disease studying and developing novel therapies. Nonetheless, iPSC-based cell therapy is presently problematic. Issues like low reprogramming efficiency, genomic instability, risk of tumorigenicity, and failure in controlling differentiation encompass significant setbacks.
MHA and Baker Tilly are hosting a briefing led by Professor Joe Nellis (Cranfield Business School), focusing on the intersection of economic trends and geopolitical risks currently impacting the UK. This short briefing will provide valuable up-to-date insights for fiscal planning, including:
- Navigating and prioritising key risks
- Capitalising on the right investments
- Optimising your business model